Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.4.2089

Mean Platelet Volume as an Independent Predictive Marker for Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer  

Mutlu, Hasan (Department of Medical Oncology, Akdeniz University School of Medicine)
Eryilmaz, Melek Karakurt (Department of Medical Oncology, Akdeniz University School of Medicine)
Musri, Fatma Yalccn (Department of Medical Oncology, Akdeniz University School of Medicine)
Gunduz, Seyda (Department of Medical Oncology, Antalya Research and Training Hospital)
Salim, Derya Kivrak (Department of Medical Oncology, Akdeniz University School of Medicine)
Coskun, Hasan Senol (Department of Medical Oncology, Akdeniz University School of Medicine)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.4, 2016 , pp. 2089-2092 More about this Journal
Abstract
Background: The impact of mean platelet volume (MPV) on prognosis, diagnosis and response to therapy in cancer patients has been widely investigated. In the present study, we evaluated whether MPV at diagnosis has predictive value for pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with locally advanced breast cancer (LABC). Materials and Methods: A total of 109 patients with LABC from Akdeniz University and Antalya Research and Training Hospital were evaluated retrospectively. Results: ROC curve analysis suggested that the optimum MPV cut-off point for LABC patients with pCR (+) was 8.15 (AUC:0.378, 95%CI [0.256-0.499], p=0.077). The patients with MPV <8.15 had higher pCR rates (29.2% vs. 13.1%, p=0.038). After binary logistic regression analysis, MPV and estrogen receptor absence were independent predictors for pCR. Conclusions: MPV has an independent predictive value for pCR after neoadjuvant chemotherapy in patients with LABC.
Keywords
Mean platelet volume; pathologic complete response; breast cancer; neoadjuvant chemotherapy;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Aliustaoglu M, Bilici A, Seker M, et al (2010). The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer. Hepatogastroenterol, 5, 640-45.
2 Bear HD, Anderson S, Smith RE, et al (2006). Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 24, 2019-27.   DOI
3 Berruti A, Amoroso V, Gallo F, et al (2014). Pathologic complete response as a potential surrogate for the clinical outcome in patients withbreast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol, 32, 3883-91.   DOI
4 Buzdar AU, Ibrahim NK, Francis D, et al (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol, 23, 3676-85.   DOI
5 Canan A, Halicioglu SS, Gurel S (2012). Mean platelet volume and D-dimer in patients with suspected deep venous thrombosis. J Thromb Thrombolysis, 34, 283-7.   DOI
6 Colleoni M, Viale G, Zahrieh D, et al (2004). Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res, 10, 6622-8.   DOI
7 Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al (2005). Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol, 23, 41-8.   DOI
8 Davi G, Patrono C (2007). Platelet activation and atherothrombosis. NEngl Jmed, 357, 2482-94.   DOI
9 Dirican A, Kucukzeybek Y, Erten C, et al (2013). Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. Asian Pac J Cancer Prev, 14, 2101-5.   DOI
10 Eryilmaz MK, Mutlu H, Salim DK, et al (2014). The neutrophil to lymphocyte ratio has a high negative predictive value for pathologic complete response in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Asian Pac J Cancer Prev, 15, 7737-40.   DOI
11 Ferlay J, Soerjomataram I, Dikshit R, et al (2012). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86.
12 Han JS, Park TS, Cho SY, et al (2013). Increased mean platelet volume and mean platelet volume/platelet count ratio in Korean patients with deep vein thrombosis. Platelets, 24, 590-3.   DOI
13 Gralow JR, Burstein HJ, Wood W , et al (2008). Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol, 26, 814-19.   DOI
14 Greisenegger S, Endler G, Hsieh K, et al (2004). Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke, 35, 1688-91.   DOI
15 Guthrie GJ, Charles KA, Roxburgh CS, et al (2013). The systemic inflammation-based neutrophil-lymphocyte ratio: 45 experience in patients with cancer. Crit Rev Oncol Hematol, 88, 218-30.   DOI
16 Inagaki N, Kibata K, Tamaki T, et al (2014). Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer, 83, 97-101.   DOI
17 Kim KI, Lee KH, Kim TR, et al (2014). Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer, 17, 40-6.   DOI
18 Kobayashi T, Teruya M, Kishiki T, et al (2008). Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery, 144, 729-35.   DOI
19 Koh YW, Lee HJ, Ahn JH, et al (2014). Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancerpatients with ER/PR-positivity and HER2- negativity in neoadjuvant setting. Tumour Biol, 35, 9823-30.   DOI
20 Kong X, Moran MS, Zhang N, et al (2011). Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer, 47, 2084-90.   DOI
21 Krauthamer M, Rouvinov K, Ariad S, et al (2013). A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol, 85, 27-32.   DOI
22 Madan SA, John F, Pitchumoni CS (2016). Nonalcoholic Fatty Liver Disease and Mean Platelet Volume: A Systemic Review and Meta-analysis. J Clin Gastroenterol, 50, 69-74.   DOI
23 Noble F, Hopkins J, Curtis N, et al (2013). The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Med Oncol, 30, 596.   DOI
24 Pistelli M, De Lisa M, Ballatore Z, et al (2015). Pre treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer, 15, 195.   DOI
25 Sansanayudh N, Anothaisintawee T, Muntham D, et al (2014). Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol, 175, 433-40.   DOI
26 Tuncel T, Ozgun A, Emirzeoglu L, et al (2014). Mean platelet volume as a prognostic marker in metastatic colorectal cancer patients treated with bevacizumab-combined chemotherapy. Asian Pac J Cancer Prev, 15, 6421-23.   DOI
27 von Minckwitz G (2013). Neoadjuvant therapy: what are the lessons so far? Hematol Oncol Clin North Am, 27, 767-84.   DOI
28 Yao M, Liu Y, Jin H, et al (2014). Prognostic value of preoperative inflammatory markers in Chinese patients with breast cancer. Onco Targets Ther, 7, 1743-52.